PDSB insider transaction filings
PDS Biotechnology Corp — 24 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-03-03. Screen PDSB transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-03-03 | 4 | BEDU-ADDO FRANK — President/CEO, Director | Grant/award (A): 548,782 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | CONN GREGORY — Chief Scientific Officer | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Shepard Kirk V. — Chief Medical Officer | Grant/award (A): 300,000 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Brown Spencer D. — Senior VP, General Counsel | Grant/award (A): 300,000 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Toutain Stephan — Chief Operating Officer | Grant/award (A): 300,000 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Freitag Gregory Gene — Director | Grant/award (A): 54,876 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Iliev Ilian — Director | Grant/award (A): 54,876 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Ali-Jackson Kamil — Director | Grant/award (A): 54,876 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Boesgaard Lars — Chief Financial Officer | Grant/award (A): 300,000 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Glover Stephen C. — Director | Grant/award (A): 54,876 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | BRAWLEY OTIS W — Director | Grant/award (A): 54,876 (derivative) @ $0 | EDGAR |
| 2025-07-25 | 4 | BEDU-ADDO FRANK — President/CEO, Director | Grant/award (A): 300,000 (derivative) @ $0 · Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2025-07-25 | 4 | Shepard Kirk V. — Chief Medical Officer | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2025-07-25 | 4 | Brown Spencer D. — Senior VP, General Counsel | Grant/award (A): 56,000 (derivative) @ $0 · Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2025-07-25 | 4 | CONN GREGORY — Chief Scientific Officer | Grant/award (A): 46,648 (derivative) @ $0 · Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2025-07-25 | 4 | Toutain Stephan — Chief Operations Officer | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2025-07-25 | 4 | Boesgaard Lars — Chief Financial Officer | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2025-06-11 | 4 | Iliev Ilian — Director | Grant/award (A): 22,700 (derivative) @ $0 | EDGAR |
| 2025-06-11 | 4 | Ali-Jackson Kamil — Director | Grant/award (A): 22,700 (derivative) @ $0 | EDGAR |
| 2025-06-11 | 4 | Freitag Gregory Gene — Director | Grant/award (A): 22,700 (derivative) @ $0 | EDGAR |
| 2025-06-11 | 4 | Glover Stephen C. — Director | Grant/award (A): 22,700 (derivative) @ $0 | EDGAR |
| 2025-06-11 | 4 | BRAWLEY OTIS W — Director | Grant/award (A): 22,700 (derivative) @ $0 | EDGAR |
| 2025-03-03 | 4 | Freitag Gregory Gene — Director | Purchase (P): 15,060 @ $1.66 · Purchase (P): 15,060 (derivative) | EDGAR |
| 2025-03-03 | 4 | Glover Stephen C. — Director | Purchase (P): 15,061 @ $1.66 · Purchase (P): 15,061 (derivative) | EDGAR |
Recent 8-K events — PDS Biotechnology Corp
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-19 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-08-14 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-11 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-31 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2026-06-15 | 8-K | 1.01 — Entry into a Material Definitive Agreement 1.02 — Termination of a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 3.02 — Unregistered Sales of Equity Securities 3.03 — Material Modification to Rights of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-15 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-06-02 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-05-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-01 | 8-K | 1.01 — Entry into a Material Definitive Agreement 1.02 — Termination of a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 3.02 — Unregistered Sales of Equity Securities | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=PDSB returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →